Core Insights - The ENSURE II study results have been published in the peer-reviewed journal Nature Medicine, evaluating the efficacy and safety of the siRNA drug elebsiran in combination with PEG-IFNα for chronic hepatitis B treatment [1] - The study also explores the potential role of the therapeutic vaccine BRII-179 in identifying immune responders and increasing HBsAg clearance rates [1] Group 1 - The ENSURE study was conducted in two parts, with the first part involving chronic HBV patients who had not previously received BRII-179, randomly assigned to either 48 weeks of PEG-IFNα monotherapy or combination therapy with elebsiran [2] - The second part involved participants who had previously received elebsiran and BRII-179, categorized based on their anti-HBs peak levels, and subsequently treated with elebsiran and PEG-IFNα [2] Group 2 - Professor Jia Jidong, the lead investigator of the ENSURE study, emphasized the study's aim to provide scientific evidence for curative therapies for chronic hepatitis B and highlighted encouraging trends in the 24-week follow-up data supporting the clinical benefits of elebsiran [3] - The study suggests a potential new role for BRII-179 in activating the immune response in chronic HBV patients, aiming for higher functional cure rates [3]

Core Insights - The core focus of the news is the publication of the ENSURE II study results, which evaluates the efficacy and safety of the siRNA drug elebsiran in combination with PEG-IFNα for the treatment of chronic hepatitis B virus (HBV) infection [1][2] Group 1: Study Overview - The ENSURE study was conducted in two parts, assessing chronic HBV patients with viral suppression [2] - In the first part, participants who had not received BRII-179 were randomly assigned to either 48 weeks of PEG-IFNα monotherapy or a combination treatment with elebsiran (administered every 4 weeks at doses of 200mg or 100mg) [2] - The second part involved participants who had previously received elebsiran combined with BRII-179, categorized based on their anti-HBs peak levels, and subsequently treated with elebsiran (100mg every 4 weeks) and weekly PEG-IFNα for 48 weeks [2] Group 2: Publication Details - The study results have been published in the peer-reviewed journal Nature Medicine, under the title "elebsiran and PEG-IFNα treatment for chronic hepatitis B virus infection: a partially randomized, open-label phase II clinical trial" [1] - The research also explores the potential role of the therapeutic vaccine BRII-179 in identifying immune responders and enhancing the HBsAg clearance rate [1]

Brii Biosciences Limited 騰盛博藥生物科技有限公司 （於開曼群島註冊成立的有限公司） （股份代號：2137） 自願性公告 在《自然•醫學》發表ENSURE II期研究結果 本公告乃由騰盛博藥生物科技有限公司（「本公司」）董事會（「董事會」）自願作出。 董事會欣然宣佈，ENSURE II期研究結果已發表於同行評審期刊《自然•醫學》。研 究評估了siRNA藥物elebsiran聯合聚乙二醇干擾素α（「PEG-IFNα」）治療方案的有 效性和安全性，並將PEG-IFNα單藥治療方案作為對照組。此外，該研究還探討了 乙型肝炎病毒（「HBV」）治療性疫苗BRII-179在識別免疫應答患者及提高乙肝表面 抗原（「HBsAg」）清除率方面的潛在作用。 標題為《elebsiran和PEG-IFNα治療慢性乙型肝炎感染：一項部分隨機、開放標籤 的II期臨床試驗》的文章現已上線。 ENSURE研究在病毒抑制的慢性HBV患者中分兩部分進行。在第一部分（隊列 1-3）中，未接受過BRII-179給藥的參與者被隨機接受48週的PEG-IFNα單藥治 療，或聯合elebsiran治療（每4週給藥一次「( Q4W」 ...

FF301 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年10月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 騰盛博藥生物科技有限公司(於開曼群島註冊成立的有限公司) 呈交日期: 2025年11月5日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02137 | 說明 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 1,200,000,000 | USD | 0.000005 | USD | | 6,000 | | 增加 / 減少 (-) | | | | | | USD | | | | 本月底結存 | | | 1,200,000,000 | USD | 0.000005 | USD | | 6,000 | 本月底法 ...

腾盛博药-B(02137)发布公告，于2025年10月31日，公司根据2023年购股权计划条款向受让人授出60万 份购股权，但须待受让人接纳。于本公告日期，已发行股份总数为7.209亿股(不包括库存股)。根据授出 购股权授出的该等购股权获悉数行使后，据此将配发及发行的股份占本公告日期已发行股份总数(不包 括库存股)约0.08%及经扩大已发行股份总数约0.08%(不包括库存股)。 ...

智通财经APP讯，腾盛博药-B(02137)发布公告，于2025年10月31日，公司根据2023年购股权计划条款向 受让人授出60万份购股权，但须待受让人接纳。于本公告日期，已发行股份总数为7.209亿股(不包括库 存股)。根据授出购股权授出的该等购股权获悉数行使后，据此将配发及发行的股份占本公告日期已发 行股份总数(不包括库存股)约0.08%及经扩大已发行股份总数约0.08%(不包括库存股)。 ...

Core Viewpoint - The company, Tengsheng Bo Pharmaceutical-B (02137.HK), announced the granting of 600,000 stock options to assignees under the 2023 stock option plan, pending acceptance by the assignees [1] Summary by Relevant Sections - **Stock Options Granted** - The company will grant 600,000 stock options to assignees, subject to their acceptance [1] - **Current Share Information** - As of the announcement date, the total number of issued shares is 720,936,585 (excluding treasury shares) [1] - **Impact of Stock Options** - If all granted stock options are exercised, the new shares will represent approximately 0.08% of the total issued shares as of the announcement date (excluding treasury shares) and approximately 0.08% of the enlarged total issued shares (excluding treasury shares) [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 於2025年10月31日，本公司根據2023年購股權計劃條款向受讓人授出600,000份 購股權，惟須待受讓人接納。於本公告日期，已發行股份總數為720,936,585股 （不包括庫存股）。根據授出購股權授出的該等購股權獲悉數行使後，據此將配發 及發行的股份佔本公告日期已發行股份總數（不包括庫存股）約0.08%及經擴大已 發行股份總數約0.08%（不包括庫存股）。 授出購股權的詳情 向受讓人授出購股權的詳情載列如下： 授出購股權的代價 : 1.00港元 購股權的行使價 : 每股股份1.82港元（相等於下列最高者：(i)聯交所於 授出日期發佈的每日報價表所列示的每股股份收市 價1.82港元；(ii)聯交所於緊接授出日期前五個營業 日發佈的每日報價表所列示的每股股份平均收市價 1.818港元；及(iii) 0.000005美元，即一股股份面值） 股份於授出日期的 : 每股股份1.82港元 收市價 Brii ...

Group 1 - The article provides a list of companies and their respective activities related to shareholder meetings, new stock activities, performance announcements, and dividend distributions scheduled for October 30, 2025 [1][2][5][7]. - Several companies are mentioned as being in the process of initial public offerings (IPOs), including 旺山旺水-B, 均胜电子, 文远知行-W, and 赛力斯 [6]. - Companies such as 美的集团 and 翰森制药 are noted for their dividend distribution dates, indicating ongoing shareholder returns [7][8]. Group 2 - The article highlights the resumption of trading for companies like 舍图控股, 鸿盛昌资源, and 安能物流, suggesting a return to market activity after previous suspensions [6][7]. - The document lists various companies involved in dividend payouts, which may attract investor interest due to potential income generation [8]. - The presence of multiple companies in the IPO stage indicates a potentially active market environment for new investments [6].

Core Viewpoint - The company, Tengsheng Bo Pharmaceutical-B (02137), announced the granting of stock options and restricted share units as part of its 2023 incentive plans [1] Group 1: Stock Options - The company granted a total of 10.1205 million stock options to 79 option grantees according to the terms of the 2023 stock option plan [1] Group 2: Restricted Share Units - The company awarded a total of 2.114 million restricted share units to 8 grantees under the 2023 restricted share unit plan [1]